Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone

BACKGROUND: Pancreatic cancer is a highly malignant tumor with a poor prognosis. Chemotherapy such as gemcitabine is still an important treatment. Gemcitabine (Gem) may prolong survival time and delay the development of recurrent disease after complete resection of pancreatic cancer. Currently, some...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hua, He, Ruizhi, Shi, Xiuhui, Zhou, Min, Zhao, Chunle, Zhang, Hang, Qin, Renyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199735/
https://www.ncbi.nlm.nih.gov/pubmed/30352573
http://dx.doi.org/10.1186/s12885-018-4948-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199735/
https://www.ncbi.nlm.nih.gov/pubmed/30352573
http://dx.doi.org/10.1186/s12885-018-4948-7

Ejemplares similares